Acelyrin gathers $120m Series B

Acelyrin, a clinical-stage biopharma company, has raised $250 million in Series B financing.

Acelyrin, a clinical-stage biopharma company, has raised $250 million in Series B financing. The lead backers were AyurMaya, an affiliated fund of Matrix Capital Management, Surveyor Capital and Westlake Village BioPartners.

Source: Press Release